Intervention Review

You have free access to this content

Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria

  1. Aika AA Omari1,*,
  2. Carrol L Gamble2,
  3. Paul Garner3

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 20 JAN 2010

Assessed as up-to-date: 19 JAN 2006

DOI: 10.1002/14651858.CD005965

How to Cite

Omari AAA, Gamble CL, Garner P. Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD005965. DOI: 10.1002/14651858.CD005965.

Author Information

  1. 1

    Alder Hey Children's Hospital, Liverpool, UK

  2. 2

    University of Liverpool, Centre for Medical Statistics and Health Evaluation, Liverpool, UK

  3. 3

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, Merseyside, UK

*Aika AA Omari, Alder Hey Children's Hospital, Eaton Road, Liverpool, L12 2AP, UK. aomari@nhs.net. aika@omari1677.freeserve.co.uk.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 20 JAN 2010

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 1 Total failure by day 14.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 2 Total failure by day 14 (excluding new infections).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 3 Gametocyte carriage by day 4.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 4 Gametocyte carriage by day 15.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Artemether-lumefantrine (4 doses) versus mefloquine, Outcome 1 Total failure by day 28.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Artemether-lumefantrine (4 doses) versus mefloquine, Outcome 2 Gametocyte carriage within the first 72 h.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Artemether-lumefantrine (4 doses) versus halofantrine, Outcome 1 Total failure by day 28.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Artemether-lumefantrine (4 doses) versus halofantrine, Outcome 2 Gametocyte carriage within the first 72 h.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Artemether-lumefantrine (4 doses) versus chloroquine, Outcome 1 Total failure by day 28.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Artemether-lumefantrine (4 doses) versus chloroquine, Outcome 2 Gametocyte carriage within the first 72 h.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 1 Total failure by day 28.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 2 Total failure by day 28 (excluding new infections).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 3 Total failure by day 63.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 4 Gametocyte carriage within the first 72 h.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Artemether-lumefantrine (4 doses) versus artemether-lumefantrine (6 doses), Outcome 1 Total failure by day 28.